The Lung Transplant Rejection drugs in development market research report provides comprehensive information on the therapeutics under development for Lung Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lung Transplant Rejection. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued products.

GlobalData tracks 13 drugs in development for Lung Transplant Rejection by 13 companies/universities/institutes. The top development phase for Lung Transplant Rejection is phase ii with six drugs in that stage. The Lung Transplant Rejection pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Lung Transplant Rejection pipeline products market are: Radikal Therapeutics, Bristol-Myers Squibb and Takeda Pharmaceutical.

The key targets in the Lung Transplant Rejection pipeline products market include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16), Beta Nerve Growth Factor (Beta NGF or NGF), and Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1).

The key mechanisms of action in the Lung Transplant Rejection pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with two drugs in Phase III. The Lung Transplant Rejection pipeline products include seven routes of administration with the top ROA being Inhalational and six key molecule types in the Lung Transplant Rejection pipeline products market including Small Molecule, and Cell Therapy.

Lung Transplant Rejection overview

Lung transplantation is the therapy used in various lung diseases. A lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously that prevent the body from either identifying or attacking the foreign organ via various immune responses, thus blocking organ rejection and facilitating a successful transplant.

For a complete picture of Lung Transplant Rejection’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.